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Abstract
Subacute sclerosing panencephalitis (SSPE) is a persistent, progressive, and fatal degen-
erative disease resulting from persistentmeasles virus (MV) infection of the central nervous
system. Most drugs used to treat SSPE have been reported to have limited effects. There-
fore, novel therapeutic strategies are urgently required. The SSPE virus, a variant MV
strain, differs virologically fromwild-typeMV strain. One characteristic of the SSPE virus is
its defective production of cell-free virus, which leaves cell-to-cell infection as the major
mechanism of viral dissemination. The fusion protein plays an essential role in this cell-to-
cell spread. It contains two critical heptad repeat regions that form a six-helix bundle in the
trimer similar to most viral fusion proteins. In the case of human immunodeficiency virus
type-1 (HIV-1), a synthetic peptide derived from the heptad repeat region of the fusion pro-
tein enfuvirtide inhibits viral replication and is clinically approved as an anti-HIV-1 agent.
The heptad repeat regions of HIV-1 are structurally and functionally similar to those of the
MV fusion protein.We therefore designed novel peptides derived from the fusion protein
heptad repeat region of the MV and examined their effects on the measles and SSPE virus
replication in vitro and in vivo. Some of these synthetic novel peptides demonstrated high
antiviral activity against both the measles (Edmonston strain) and SSPE (Yamagata-1
strain) viruses at nanomolar concentrations with no cytotoxicity in vitro. In particular, intra-
cranial administration of one of the synthetic peptides increased the survival rate from 0% to
67% in an SSPE virus-infected nude mousemodel.
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Introduction
The measles virus (MV) is a nonsegmented negative-strand RNA virus that belongs to the fam-
ily Paramyxoviridae in the genusMorbillivirus. MV has six transcription units—N, P, M, F, H,
and L genes—which encode nucleocapsid (N), phospho (P), matrix (M), fusion (F), hemagglu-
tinin (H), and large polymerase (L) proteins. Ribonucleoprotein complexes are comprised of
the N, P, and L proteins, as well as the viral RNA genome [1–3]. The P locus also encodes non-
structural V and C proteins functioning as virulence factors [4]. The H protein is associated
with binding to host cell receptors, such as CD46 [5] and PVRL4 (Nectin 4) [6], as well as
CD150 (SLAM, signaling via the lymphocyte activation molecule) [7]. The M protein promotes
virus particle formation and maturation, whereas the F protein is associated with membrane
fusion [1, 2]. The F protein of MV is initially synthesized as a precursor, F0, which is subse-
quently cleaved into F1 and F2 by a furin-like protease in the host cell, although they remain
linked by a disulfide bond [8]. It also possesses two highly conservedheptad repeat (HR)
regions, HR1 and HR2 [9, 10]. After binding to the host cell receptor via the H protein, mem-
brane fusion occurs via a conformational change in the F protein. Thus, HR1 and HR2 interact
to form a six-helix coiled-coil bundle, which is centered on HR1 and surrounded by HR2 [9].
Subacute sclerosing panencephalitis (SSPE) is a rare, but slow viral infection that affects the
central nervous system of the fetus, which is caused by persistent MV infection that continues
several years after the initial acute infection. It results in extensive cognitive disorders, lapse
into vegetative state, and death [11]. Although SSPE is very rare since the widespread introduc-
tion of measles vaccines in developed countries [12], it remains an important disease due to its
poor prognosis and the absence of an established treatment. Several drugs, such as inosiplex
[13, 14] and interferon-α (IFN-α) [15, 16], have been reported to be therapeutic, although they
are not curative. Recently, intraventricular ribavirin administration was shown to suppress the
spread of the SSPE virus in the central nervous system and block the progression of SSPE syn-
drome [17–19], although definitive evidence of its clinical efficacy is lacking. Therefore, novel
therapeutic strategies are required.
MV strains isolated from patients with SSPE differ virologically from the wild-typeMV
strain. The SSPE virus has strong neurovirulence and is defective in the production of cell-free
infectious virus, which leads to its dissemination via cell-to-cell infection. Autopsy findings of
SSPE patients suggested that SSPE virus transmitted via trans-synaptic transmission, and thus,
it did not form syncytia [20]. The interaction of F protein with neurokinin-1 triggers a microfu-
sion at the synapse, resulting in trans-synaptic transmission [21]. M protein mutations are
associated with these virological characteristics and with SSPE virus pathogenesis [1, 22, 23].
The F protein plays an important role in cell-to-cell infection and is also associated with its
neurovirulence [24].
In the case of human immunodeficiencyvirus type-1 (HIV-1), conformational changes in
the envelope glycoprotein gp41, which comprises two α-helical domains—the N-terminal hep-
tad repeat (N-HR) and the C-terminal heptad repeat (C-HR)—have essential roles in the viral
fusion process. During fusion, N-HR forms a trimeric coiled-coil surrounded by three C-HRs
[25, 26]. For HIV-1, it has been reported that peptides derived from the HR2 of glycoprotein
gp41 inhibit viral fusion with the host cell membrane. Some of these peptides, such as enfuvir-
tide (also referred to as T-20 or DP178 in other studies) have been confirmed to be safe and
efficacious and have been clinically utilized as anti-HIV agents for treatment [27]. Recently,
some studies have shown that stabilization of the α-helix structure of these peptides has an
important role in their antiviral activity. The introduction of a salt bridge formation between
two adjacent amino acid residues is one approach for stabilizing the α-helix structure [28–31].
Oishi et al. reported that enfuvirtide containing glutamate (E) and lysine (K) substitutions to
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introduce this salt bridge formation retained stable α-helicity and exhibited highly potent anti-
HIV activity [29].
The structure–functionrelationships of the fusion protein HR regions are similar in retrovi-
ruses and paramyxoviruses (Fig 1A) [10, 32]. Lambert et al. identified conservedHR regions
within the fusion proteins of paramyxoviruses, includingMV, which corresponded to the HR
regions of HIV-1 gp41. They also reported that some of the peptides derived from the para-
myxovirus fusion protein region had highly selective antiviral activities in vitro [10]. Similar
results have been reported for overlapping peptides in MV [9, 33], but there are no reports of
their antiviral effects in the SSPE virus.
In this study, we synthesized novel peptides derived from the fusion protein HR2 region of
MV and evaluated their inhibitory effects on the replication of the measles and SSPE virus in
vitro and in vivo.
Materials andMethods
Cells, media, and viruses
African greenmonkey kidney (Vero) cells and Vero cells expressing human SLAM (Vero/
SLAM cells) were used in all experiments. The growth medium for Vero cells comprisedmini-
mal essential medium (MEM) supplemented with 10% heat-inactivated newborn bovine
serum, penicillinG (100 IU/ml), streptomycin (100 μg/ml), and L-glutamine (300 μg/ml). The
same growth medium, which was further supplemented with G418 (400 μg/ml), was used for
Vero/SLAM cells. Cells were seeded into the wells (22 mm) of 12-well tissue culture plates at
1 × 105 cells/well and incubated at 37°C in a 10% CO2 incubator for 3 days, at which time they
had just reached confluence. The virus strains used were human MV Edmonston strain and
SSPE Yamagata-1 [34], which was originally isolated from the brain of an SSPE patient. The
Edmonston strain of MV was used to inoculate Vero/SLAM cells and harvested after freeze–
thawing infected cells. The SSPE Yamagata-1 strain was cultured in Vero/SLAM cells, har-
vested by trypsinization, prepared as an infected cell suspension in the Vero/SLAM cell
medium supplemented with 10% dimethyl sulfoxide, and stored at −80°C until use.
Gene sequence analysis
Viral RNA was extracted from the MV Edmonston and SSPE Yamagata-1 strains using ISO-
GEN-LS (Nippon Gene, Tokyo, Japan). After RNA extraction, cDNA was synthesized using a
reverse transcription kit (PrimeScript RT-PCR kit, TaKaRa, Shiga, Japan), and PCR was per-
formed using TaKaRa Ex Taq1 HS according to the manufacturer’s instructions. Primers tar-
geting the coding regions of F genes were synthesized, as previously described [35]. PCR
products were separated by 2% agarose gel electrophoresis, and the bands of interest were
excised. DNA was purified using a QIAquick Gel ExtractionKit (Qiagen, Hilden, Germany),
and the direct sequence analysis of F genes was performed using a DYEnamic ET Terminator
Cycle SequencingKit (GE Healthcare, Tokyo, Japan). Sequence data were then analyzed using
GENETYXVer. 10 (Genetyx Corporation, Tokyo, Japan). The amino acid sequence was
deduced from the nucleotide sequence using the GENETYX software.
Peptide synthesis
Eight peptides derived from the HR2 region based on the amino acid sequence data for the MV
Edmonston strain were synthesized.M1, M3, and M4, which are peptides with antiviral activity
against the MV Edmonston strain, were synthesized, as previously reported [10]. M2 is a novel
peptide with the same length (35 amino acids) as that of M1, M3, and M4. Peptides with an EK
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Fig 1. Fusionprotein of themeasles virus andHIV-1 and amino acid sequences ofmeasles virus heptad repeat (HR) regions. (A) A
schematic of the HIV-1 transmembrane protein andmeasles virus fusion protein showing the locations of structurally significant domains,
including the HR region. There are structural and functional similaritiesbetween the measles virus and HIV-1 virus. Amino acid sequence
data for themeasles virusHR1 region (positions 145–184) (B) and the HR2 region (positions 445–493) (C). Amino acid sequence data on
measles virus strains were selected based onMeasles SurveillanceData of World Health Organization that were currently active measles
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motif, i.e., M1EK,M2EK, M3EK, and M4EK, were also novel synthetic peptides that possessed
α-helix structures stabilized by the formation of a salt bridge. Salt bridge formation was
induced by replacing amino acids at solvent-accessible sites of the helical bundle with gluta-
mate (E) and lysine (K), while maintaining those at the interactive sites because these are criti-
cal for interactions with the HR1 region. E and K were arranged at the e/f and b/c positions,
respectively (Fig 2A), yielding a repeat of X-EE-XX-KK (X indicates the original amino acid)
motifs.
All peptides were synthesized as N-terminally acetylated and C-terminally amidated forms
using standard 9-fluorenylmethoxy carbonyl-based solid-phase techniques [30]. Peptide sam-
ples were prepared for biological tests by high-performance liquid chromatographic purifica-
tion of crudematerials on a preparative Cosmosil 5C18 AR-II column (Nacalai Tesque Inc.,
Kyoto, Japan) using a linear gradient of H2O/acetonitrile containing 0.1% trifluoracetic acid.
Enfuvirtidewas purchased from Genentech Inc. and Trimeris Inc., (San Francisco, CA, USA).
The amino acid sequence of enfuvirtide is as follows:
YTSLIHSLIEESQNQQEKNEQLLELDKWASLWNWF.
Screening and 50% effective concentration determination
Screeningwas performed to evaluate the antiviral effects of each synthetic peptide against the
MV and SSPE viruses using the viral plaque reduction assay. Based on the results of the peptide
screening, the 50% effective concentration (EC50), i.e., the concentration of compounds
required to inhibit virus plaque formation by 50%, was also determined. The Human MV
Edmonston strain was used to produce cell-free virions, which yielded a reproducible number
of syncytia [generally 200–300 plaque-forming units (PFUs)] in the control wells. The SSPE
virus was also used to yield a reproducible number of syncytia (generally 70–150 PFU) in con-
trol wells. In the peptide screening assay, each synthetic peptide was used at a concentration of
10 μM. IFN-α and enfuvirtide, a peptide fusion inhibitor of HIV-1, were used as controls at a
concentration of 250 IU/ml and 10 μM, respectively.
Cytotoxicity assays
Peptide cytotoxicity was determined using the methyl tetrazolium assay. Five-fold serial dilu-
tions of peptides were added to confluent Vero or Vero/SLAM cells. Cells were then incubated
at 37°C for 24 h, and the number of viable cells was determined using 3-(4,5-dimethyllthiazol-
2-yl)-2,5-diphenylterazolium bromide (Sigma–Aldrich, Tokyo, Japan). The 50% cytotoxic con-
centration (CC50), which was defined as the concentration required to reduce the cell viability
by 50% relative to that of untreated controls, was determined. The selectivity index (SI) was
defined as the ratio of the CC50 relative to the EC50 value.
Time-of-additionexperiments
Synthetic peptides,M1 and M2EK (10 μM each) were used in time-of-addition experiments.
Each peptide was added to Vero cells at three distinct time points: prior to infection
virus clades worldwide. (http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_
monthlydata/en/) The letters in red show the amino acid substitution points comparedwith the Edmonston strain. The amino acid sequences
in the lower column represent those of the HR regions of the Edmonston and SSPE Yamagata-1 strains used in our experiments. The amino
acid position numbers shown here relate to theMV Edmonston strain sequence, which is available in the UniProtKB/Swiss-Prot database
under accession number P69353. The amino acid sequences of other viruseswere derived from the GenBank and DDBJ databases under
the following accession numbers: New Jersey.USA/45.05, JN635408; Treviso.ITA /03.10/1, KC164757; Virginia.USA/15.09, JN635404.1;
Venice.ITA/06.11/1, KC164758; Pennsylvania.USA/20.09, JN635411; Kobe-1, AB254456; OSA-1, AF179433;OSA-2, AF179436; Kitaken,
AB453046; and Yamagata-1, D10548.
doi:10.1371/journal.pone.0162823.g001
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Fig 2. Peptide synthesis and screening. (A) The preorderedα-helix structureof the synthetic peptidewith salt bridge formation.Glutamate
(E) and lysine (K) were introduced into solvent-accessible sites (the e/f and b/c positions, respectively) to induce salt bridge formation,while
maintaining the amino acids in the interactive sites, thereby resulting in a repeat of X-EE-XX-KK (X indicates the original amino acid) motifs.
(B) Amino acid sequences of synthetic peptides derived from theMV Edmonston strain HR2 domain.M1EK,M2EK, M3EK, andM4EK, in
which the α-helix structure is stabilized by the formation of a salt bridge, are synthetic peptides based on peptidesM1, M2,M3, andM4,
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(pretreatment with the compound), at the same time as the virus infection (simultaneous infec-
tion), or post-infection (post-entry). The SSPE virus was prepared to yield a reproducible num-
ber of syncytia in untreated control wells (approximately 50–100/well). In the pretreatment
assay, peptide was added to confluent cells and incubated at 37°C for 30 min, and the cell cul-
tures were washed with MEM before viral inoculation. Cells were then challenged with the
SSPE virus at 0°C for 30 min. In the simultaneous infection assay, SSPE virus with peptide was
inoculated at 0°C for 30 min. After the adsorption, the cell cultures were subsequently washed
with MEM, and growth medium containing 0.75%methylcellulose was overlaid on the cell cul-
tures, followed by incubation for 3 days in both pretreatment and simultaneous infection
assays. In the post-entry assay, cells were challenged with the SSPE virus at 0°C for 30 min.
After adsorption, the cell cultures were subsequently washed with MEM and peptide, which
was prepared in growth medium containing 0.75%methylcellulose, was subsequently overlaid
on the cell cultures at distinct time points. The starting point when cells were incubated at 0°C
for 30 min was defined as t0.
Animal survival experiments
Based on a previous report [36], but with slight modifications, 3-week-old female BALB/cAJcl-
nu/nu mice (CLEA Japan Inc., Tokyo, Japan) were used in the animal experiments.Mice were
divided in four groups (n = 6 for each cage) and housed with free access to both water and food
and monitored daily. The mice were SSPE virus-infectedor mock-infected (MEM alone) intra-
cranially. An SSPE virus-infectedcell suspension containing 250 PFU/ 30 μl (100% lethal dose)
was inoculated into the subarachnoid space of nude mice using a 27-gauge double needle at a
depth of 2 mm. Each compound was prepared at a concentration of 100 μM and was injected
intracranially at 0 (mixed with viruses), 6, and 24 h after the initial virus inoculation.All injec-
tions were performed under inhalational anesthesia with isoflurane. Each mouse was checked
for neurological symptoms and weighed daily. The ethical endpoint was defined as<75% of
their maximumweight becausemost mice would die within 24 h. On attaining this endpoint,
the mice were sacrificedby cervical dislocation under inhalational anesthesia with isoflurane.
In this experiment, five mice died of natural causes before the ethical endpoint; however, all
mice had neurological symptoms and 9.5%, 13.2%,14.5%, 15.8%, 16.4% weight loss (one each)
relative to their maximumweight. This study was approved by the control of the Animal
Research Committee in accordance with the Guidelines on Animal Experiments in Fukushima
Medical University and the Rules for the Protection and Care of Animals (approval number:
23038).
Viral quantification
Mice were divided in three groups (n = 5 for each cage) and housed with free access to both
water and food and monitored daily. Mice were infected with SSPE virus intracranially in the
same as animal survival experiments. Euthanasia was performed by cervical dislocation under
isoflurane anesthesia on day 14 post-infection. The brain of each mouse was immediately har-
vested and mechanically homogenizedwith 2 ml Vero/SLAM cell growth medium using a
PRO200 handheld or post-mounted homogenizer (PRO Scientific Inc., CT, USA). The homog-
enized brains were stored at −80°C. Viral RNA was extracted using ISOGEN-LS, and cDNA
respectively. Enfuvirtide is a peptide fusion inhibitor of HIV-1. (C) Screening of synthetic peptide data. The vertical axis represents plaque
reduction as a percentage relative to the control group. Peptide screening was performed at a concentration of 10 μM. Enfuvirtide and
interferon-α (IFN-α)were used as a control peptide at a concentration of 10 μMand 250 IU/ml, respectively. The experiments were performed
in duplicate, and at least twice independently with similar results. Error bars indicate the standard deviation.
doi:10.1371/journal.pone.0162823.g002
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was synthesized using a reverse transcription kit (PrimeScript RT-reagent kit). MV RNA was
quantified using a TaqMan real-time polymerase chain reaction assay, as previously described
[37, 38]. The primer and probe were designed based on the MV Edmonston strain N gene, as
previously reported [39]. PCR amplification was performed using a 7300 Real-Time PCR sys-
tem (Applied Biosystem). The control plasmid was produced by Dragon Genomics Center
(Takara Bio, Mie, Japan) based on the MV Edmonston strain N gene (position 1321–1500).
Statistical analysis
All values are expressed as the mean ± standard deviation (SD). Comparisons among groups of
peptide screening data were made using one-way analysis of variance (ANOVA), followed by
Dunnett’s post-hoc test. Differences between groups were analyzed using a log rank test with
Tukey’s post-hoc test (for mortality data) or Kruskal–Wallis test with Steel-Dwass post-hoc
test (for time-of-addition date and viral RNA data). Statistical analyses were performed using
Excel Statistics 2012, Social Survey Research Information Co. Ltd., Tokyo, Japan. P< 0.05 was
considered statistically significant.
Results
Amino acid sequences of the MV Edmonston and SSPE Yamagata-1
strains
The amino acid sequences of the HR1 regions between strains were the same, or had only one
substitution, except for that of Pennsylvania.USA/20.09 strain. By contrast, zero or two amino
acid substitutions were detected between virus strains in the HR2 region (Fig 1B and 1C).
These results suggest that HR regions of the F protein are comparatively well conserved
between virus strains, particularly the HR1 region.Moreover, it has been shown that synthetic
peptides derived from the HR2 region alone could inhibit MV viral fusion [10, 33]. Thus, we
synthesized peptides derived from the HR2 region based on the amino acid sequence data for
the MV Edmonston strain. To compare the virus strains in this study with those in previous
reports, amino acid sequences of HR regions of the SSPE Yamagata-1 strain were identical to
those previously described [40], whereas two different amino acid sequences were identified in
the HR2 region of MV Edmonston strain (Fig 1B and 1C).
Peptide screening and in vitro efficacy of the novel peptide
Eight peptides were synthesized based on the amino acid sequence data for the HR2 region of
the MV Edmonston strain (Fig 2B). The eight synthetic peptides were screened at a concentra-
tion of 10 μM. The novel peptides, except for M4EK, showed statistically significant inhibition
of MV Edmonston plaque formation compared with the control group (P< 0.01; Dunnett’s
post-hoc test) (Fig 2C). In contrast, plaque numbers among all groups were significantly differ-
ent from the SSPE Yamagata-1 strain in both Vero cells (P< 0.01; ANOVA, F = 64.9) and
Vero/SLAM cells (P< 0.01; ANOVA, F = 47.4). In particular, M1, M1EK, and M2EK inhibited
plaque formation by>97% compared with the control group (P< 0.01; Dunnett’s post-hoc
test) (Fig 2C). M3EK,M4EK and Enfuvitide had lower antiviral activity against both Edmon-
ston and Yamagata-1 strains than the other peptides (Fig 2C).
Following the results of the peptide screening, we determined EC50 values of M1, M1EK,
M2, and M2EK against the MV Edmonston strain (Table 1). M1, M1EK,M2, and M2EK had
similar antiviral activity levels against the Edmonston strain.
The EC50 values of M1, M1EK,M2, and M2EK against the Yamagata-1 strain were
0.01 ± 0.01, 0.12 ± 0.05, 0.26 ± 0.17, and 0.05 ± 0.03 (μM; mean ± SD) (Table 1), respectively,
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in Vero cells and 0.01 ± 0.01, 0.17 ± 0.02, 0.48 ± 0.22, and 0.02 ± 0.01 (μM; mean ± SD)
(Table 1), respectively, in Vero/SLAM cells. M1 and M2EK had almost the same antiviral activ-
ity levels against the SSPE Yamagata-1 strain. Enfuvirtide, the control peptide derived from the
HR2 of HIV-1 gp41, had no activity against Edmonston and Yamagata-1 strains at concentra-
tions up to 10 μM. The CC50 values were>100 μM for all peptides in both Vero and Vero/
SLAM cells, and none of the synthetic peptides had any cytotoxic effect. Therefore, all peptides
had SI values in the order of several hundreds to several thousands (Table 1).
Antiviral activity mechanismof the peptide in vitro
Time-of-addition experiments were performed to determine the stage at which compounds
exerted their inhibitory effects using the synthetic peptidesM1 and M2EK.When each peptide
was added before viral adsorption or at the same time as virus inoculation, no reduction in
viral plaque numbers was detected compared with that in each control group (Fig 3A). More-
over, there were no statistically significant differences between peptides at pretreatment or
when added at the same time as virus infection (Fig 3A). These results suggest that the novel
peptides did not inhibit infection at the adsorption stage. Based on these results, we added each
peptide to cell cultures at distinct time points after viral adsorption. Vero cells were challenged
with the virus and incubated at 0°C; therefore, the virus remained at the attachment stage and
did not progress to the fusion stage. In this assay, the viral inhibitory effect of each peptide was
observed in a time-dependentmanner, particularly within 24 h (Fig 3B). This suggests that
both peptides interfere with viral fusion stage, resulting in the reduction of viral replication.
In vivo effects of the novel peptides
To confirmwhether the compound or virus had spread beneath the subarachnoid space of the
nude mice, 30μl hematoxylin was intracranially administered. Hematoxylin was found to have
spread beneath the entire subarachnoid space within 3 h of administration (Fig 4A). Based on
a previous report with slight modifications [36], we established the SSPE virus-infectednude
mouse model. In this model, symptoms such as sudden jumps, hypersensibility, convulsions,
and gait disorders were observedduring SSPE development. The nude mice then exhibited pro-
gressive weight loss, gradual loss of mobility, and finally death (Fig 4B).
M1 and M2EK, both of which exhibited antiviral efficacy in vitro, were intracranially
administered in a nude mouse model to evaluate their therapeutic efficacy and toxic effect.
Enfuvirtidewas used as a control peptide. In the control group, all nude mice died or required
euthanasia due to weight loss (range = 18–31 days post-infection). Intracranial administration
of M2EK in nude mice increased the survival rate from 0% to 67% compared with the control
Table 1. Effects of synthesized peptideson themeasles and SSPE viruses.
Measles virus (Vero cells) SSPE virus (Vero cells) SSPE virus (Vero/SLAM cells)
Peptide EC50a (μM) CC50b (μM) SIc EC50a (μM) CC50b (μM) SIc EC50a (μM) CC50b (μM) SIc
M1 0.03 ± 0.01 >100 >3663 0.01 ± 0.01 >100 >7519 0.01 ± 0.01 >100 >9524
M2 0.12 ± 0.04 >100 >805 0.26 ± 0.17 >100 >377 0.48 ± 0.22 >100 >209
M2EK 0.10 ± 0.07 >100 >989 0.05 ± 0.03 >100 >2041 0.02 ± 0.01 >100 >6579
Enfuvirtide >10 >100 - >10 >100 - >10 >100 -
aEC50, 50% effective concentration or the concentration required to reduce cell viability by 50%.
bCC50, 50% cytotoxic concentration or the concentration required to inhibit viral replication by 50%.
cSI, Selectivity index is the ratio of the 50% effective concentration to the 50% cytotoxic concentration and indicates drug tolerability in vitro.
doi:10.1371/journal.pone.0162823.t001
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group (P< 0.05). By contrast, there was no statistically significant difference in survival rate
between other pairwise groups (Fig 5A).
To further evaluate the inhibitory effect of M2EK, we determined the viral RNA copy num-
ber in whole brains on day 14 post-infection.The viral RNA copies in M2EK-treated brains
were approximately four log lower than in the brains of M1-treated mice (P< 0.05), and
approximately three log lower than in the brains of enfuvirtide-treatedmice (P< 0.05) (Fig
5B). These results suggest that M2EK spreads to the cerebral parenchyma via the subarachnoid
space and markedly inhibits the replication of the SSPE virus, thereby leading to an increased
survival rate.
Mice administered with peptides alone (M1, M2EK, and Enfuvirtide at the concentration of
100 μM each) survived for>45 days with no symptoms, indicating that these peptides show no
toxicity in vivo.
Discussion
To our knowledge, this is the first study to demonstrate that novel synthetic peptides derived
from the HR2 region of MV inhibit the replication of the SSPE virus in vitro and in vivo.
Inhibition of the fusion process is an effective strategy for SSPE treatment because the SSPE
virus is characteristically defective in the production of cell-free infectious virus, which leads to
its dissemination via cell-to-cell fusion. In this study, we demonstrated that synthetic peptides
inhibited the replication of the MV and SSPE viruses at nanomolar concentrations without any
cytotoxicity (Table 1). In addition, our study showed that the peptides inhibited viral replica-
tion by interfering with the fusion process (Fig 3).
The synthetic peptides had antiviral activity against the SSPE virus despite the fact that they
were derived from the MV Edmonston strain. During the viral fusion process, conformational
Fig 3. Effects of the novel peptideon PFU at different stages of virus infection.The synthetic peptidesM1 andM2EKwere added at three distinct
time points: prior to infection (pretreatment), at the same time as virus infection, or post-infection (post-entry). (A) Effects of each peptide administration
prior to or at the same time as virus infection: Therewas no statistically significant difference in viral plaque numbers between groups or peptides. The
experiments were performed in duplicate, three times independently and error bars represent the standard deviation of themeans. (B) Effect of each
peptide administration post-infection: The startingpoint when cells were incubated at 0°C for 30 min was defined as t0. The vertical axis represents the
percentage of plaque forming units (PFUs) for the control group in both figure panels. Both peptide inhibited viral replication during the viral fusion stage
but not during the adsorptionstage. The error bars indicate the standard deviation of three independent experiments, each performed in duplicate.
doi:10.1371/journal.pone.0162823.g003
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changes in the F protein that occur via interactions betweenHR1 and HR2 regions, to form a
stable six-helix coiled-coil bundle, are essential in paramyxoviruses. Several studies have shown
that the HR regions of the F protein are highly conserved in paramyxoviruses [41, 42]. More-
over, the highly conserved region is critical for correct F protein folding during the fusion pro-
cess [42]. These facts indicate that HR regions of the F protein are essential components; thus,
any major mutation in these regions may be fatal for the virus because they could reduce its
viral replication capability and/or infectivity. In our study, one or two amino acid substitutions
were observed in HR regions of the Edmonston and Yamagata-1 strains (Fig 1B and 1C).
Komase et al. reported that the amino acid sequence of the MV F protein shared 96.27%
Fig 4. Time course of SSPE virus-infected nudemousemodel. (A) The brains of nudemice were harvested 3 h after 30 μl intracranial hematoxylin or
normal saline administration. Hematoxylin was found to have spread beneath the subarachnoid space. (B) Nudemice exhibited weight loss 2–3 days
before death and died 16–31 days after virus inoculation.Neurological symptomswere observed shortlybefore or at the same time as weight loss began;
typical neurological symptoms in nudemice were sudden jumps, convulsions, hypersensibility, and gait disorder, but the degree of these symptoms was
different for eachmouse.
doi:10.1371/journal.pone.0162823.g004
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homology with the SSPE Yamagata-1 strain [40]. This supports the fact that amino acid
sequences of HR regions of the SSPE virus, an MV variant, are well conserved compared with
MV; therefore, synthetic peptides derived from HR regions of the MV F protein also had anti-
viral activity against the SSPE virus.
We also observed that M2EK, which is formed through the introduction of an EKmotif
into M2, exhibited higher antiviral activity against the MV and SSPE viruses than doesM2 in
vitro. These results suggest that the introduction of the EKmotif into the HR2 peptide
increased its binding affinity to the HR1 region of the MV fusion protein. Several reports have
shown that introduction of EK substitution to synthetic peptides at solvent-accessible sites
retain an α-helical conformation and increased the binding affinity for target the HR1 regions
of wild-type and mutant viruses [29, 31, 43]. It is possible that M2EK possesses these
physicochemical properties, but not M2. However, the other three peptides with the EKmotif,
i.e., M1EK,M3EK, and M4EK, had lower antiviral activities than did each parent peptide. EK
substitutions in these peptidesmay induce critical conformational changes, thereby resulting
in a low binding affinity or altering contacts to the HR1 region.
M1 and M2EK had almost the same antiviral activity levels against the SSPE Yamagata-1
strain at nanomolar concentrations in vitro, but only M2EK administration increased the
Fig 5. Effects of synthesized peptideson the SSPE virus in nudemice. (A) 24 nude mice (n = 6 for per group) were intracranially infected with the
SSPE Yamagata-1 strain and administeredM1, M2EK, or enfuvirtide. Controlmice were administeredminimal essential mediumalone. The difference in
the survival rate of mice receiving M2EKwas statistically significant comparedwith that of control mice, whereas therewas no statistically significant
difference in survival rate between other pairwise groups (P < 0.05, log rank test for survival curves; post-hoc comparisons with Tukey’s test). (B) 15 nude
mice (n = 5 per group) were intracranially infected with the SSPE Yamagata-1 strain and administeredM1,M2EK, or enfuvirtide. Viral RNA copies in each
entire brain were quantified on day 14 post-infection. Error bars indicate the standard error of themean. *P < 0.05; Kruskal–Wallis test, Steel–Dwass
post-hoc test.
doi:10.1371/journal.pone.0162823.g005
Novel Peptide Inhibits Replication of SSPE Virus
PLOSONE | DOI:10.1371/journal.pone.0162823 September 9, 2016 12 / 16
survival rate and inhibited viral replication in the nude mouse model (Fig 5). In the in vivo
assay, the thermal stability of peptides would be important for antiviral activity. Naito et al.
reported that synthetic peptides with an EK substitution exhibit sufficiently high thermal sta-
bility to target the HR1 region, which results in highly potent antiviral activities against wild-
type and mutant viruses that are resistant to those without the EKmotif [31]. There are no pre-
vious reports on pharmacokinetic and pharmacodynamic differences in vivo between synthetic
peptides with or without EK substitution, but differences in these pharmacokinetic and phar-
macodynamic characteristics, such as the metabolism rate of peptides,may contribute to differ-
ences in the inhibition of viral replication in vivo.
In summary, the novel peptideM2EK, which was derived from the HR2 region, inhibited
the replication of the SSPE virus by interfering with its fusion process in vitro and in vivo. The
inhibition of the viral fusion process during infectionmay be a useful strategy for the treatment
of incurable diseases, such as SSPE. Thus, M2EKmay be a new candidate for SSPE treatment.
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